Advancements in the treatment of metastatic hormone-sensitive prostate cancer

Abstract

In the last decade, there have been substantial improvements in the outcome of the management of metastatic hormone-sensitive prostate cancer (mHSPC) following the development of several novel agents as well as by combining several therapeutic strategies. Although the overall survival (OS) of mHSPC is shown to improve with intense androgen deprivation therapy (ADT), combined with docetaxel, as well as other novel hormonal therapy agents, or alongside local intervention to the primary neoplasm. Notably, luteinizing hormone-releasing hormone (LHRH) antagonists are known to cause fewer cardiovascular side effects compared with LHRH agonists. Thus, in this mini review, we explore the different approaches in the management of mHSPC, with the aim that we may provide useful information for both basic scientists and clinicians when managing relevant clinical situations.

Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models

“…As a semisynthetic taxane, docetaxel exhibits significant single-agent activity against PCa, mainly by inhibiting microtubules polymerization and inducing cell cycle arrest at the G2/M phase and subsequent apoptosis [7] . In recent trials, the combined use of docetaxel and ADT significantly improved the overall survival of patients with metastatic, hormone-sensitive PCa, particularly with high tumor volumes [ 8 , 9 ]. These promising data indicated that docetaxel would remain a mainstay for the clinical management of PCa [10] .…”